Evidence map›Paper›PMID 36325075›Full record

ArticleiScience2022

Polyvalent guide RNAs for CRISPR antivirals.

Rammyani Bagchi, Rachel Tinker-Kulberg, Mohammad Salehin, Tinku Supakar, Sydney Chamberlain, Ayalew Ligaba-Osena, Eric A Josephs

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. CRISPR Diagnostics, in Your Pocket.Journal of medical Internet research · 2026
    Article
  3. Review
  4. TOP-SECRETS enables Cas9 nucleases to discriminate SNVs outside of PAMs.bioRxiv : the preprint server for biology · 2025
    Article
  5. Review
  6. Article
  7. Review
  8. Insights Gained from RNA Editing Targeted by the CRISPR-Cas13 Family.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Rammyani BagchiDepartment of Nanoscience, The University of North Carolina at Greensboro, Greensboro, NC 27401, USA.
Rachel Tinker-KulbergDepartment of Nanoscience, The University of North Carolina at Greensboro, Greensboro, NC 27401, USA.
Mohammad SalehinDepartment of Nanoscience, The University of North Carolina at Greensboro, Greensboro, NC 27401, USA.
Tinku SupakarDepartment of Nanoscience, The University of North Carolina at Greensboro, Greensboro, NC 27401, USA.
Sydney ChamberlainDepartment of Biology, The University of North Carolina at Greensboro, Greensboro, NC 27401, USA.
Ayalew Ligaba-OsenaDepartment of Biology, The University of North Carolina at Greensboro, Greensboro, NC 27401, USA.
Eric A JosephsDepartment of Nanoscience, The University of North Carolina at Greensboro, Greensboro, NC 27401, USA.
University of North Carolina at Greensboro · US

Funding

MOLECULAR GENETICS OF AUXIN ACTION IN ARABIDOPSISR01GM043644 · NIGMS · UNIVERSITY OF TEXAS AUSTIN · PI ESTELLE, MARK A · 1989 to 2021
$6.0M
Complex Mechanisms of Mutation and Mutation Avoidance in Living CellsR35GM133483 · NIGMS · UNIVERSITY OF NORTH CAROLINA GREENSBORO · PI JOSEPHS, ERIC ALAN · 2019 to 2023
$1.6M
NIGMS NIH HHS R01 GM043644NIGMS NIH HHS R35 GM133483
6 · The paper itself

Abstract

CRISPR effector Cas13 recognizes and degrades RNA molecules that are complementary to its guide RNA (gRNA) and possesses potential as an antiviral biotechnology because it can degrade viral mRNA and RNA genomes. Because multiplexed targeting is a critical strategy to improve viral suppression, we developed a strategy to design of gRNAs where individual gRNAs have maximized activity at multiple viral targets, simultaneously, by exploiting the molecular biophysics of promiscuous target recognition by Cas13. These "polyvalent" gRNA sequences ("pgRNAs") provide superior antiviral elimination across tissue/organ scales in a higher organism (

Indexed as

Biocomputational methodBiological sciences toolsComputational bioinformatics

Identifiers

PMID36325075
PMCPMC9618770
OpenAlexW4304944595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.